Genetics may shape GLP-1 outcomes, slightly

Summary: The biotech world is facing a lot of changes right now. Steve Ubl, the CEO of PhRMA, is stepping down from his position. At the same time, biotech investors are feeling stressed. Even though they have large amounts of cash saved up, they are facing tough new competition from artificial intelligence (AI) and Chinese labs. In government news, the Trump administration is backing away from a fight over indirect costs at the National Institutes of Health (NIH). Finally, new medical data shows that your genetics might have a small effect on how your body responds to popular GLP-1 weight-loss drugs.

For more details, see rssapp-statnews-com at statnews.com/2026/04/09/biotech-news-genetics-may-shape-glp-1-outcomes-slightly/ (opens in new tab)